Genetic restriction of human immunodeficiency virus-type 1 infection and progression to acquired immunodeficiency syndrome by a deletion allele of the chemokine receptor 5 structural gene
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The chemokine receptor 5 (CKR5) protein serves as a secondary receptor on CD4^+^ T lymphocytes for certain strains of human immunodeficiency virus-type 1 (HIV-1). The CKR5 structural gene was mapped to human chromosome 3p21, and a 32-base pair deletion allele (CKR5Δ32) was identified that is present at a frequency of \~0.10 in the Caucasian population of the United States. An examination of 1955 patients included among six well-characterized acquired immunodeficiency syndrome (AIDS) cohort studies revealed that 17 deletion homozygotes occurred exclusively among 612 exposed HIV-1 antibody-negative individuals (2.8%) and not at all in 1343 HIV-1-infected individuals. The frequency of CKR5 deletion heterozygotes was significantly elevated in groups of individuals that had survived HIV-1 infection for more than 10 years, and in some risk groups, twice as frequent as their occurrence in rapid progressors to AIDS. Survival analysis clearly shows that disease progression is slower in CKR5 deletion heterozygotes than in individuals homozygous for the normal CKR5 gene. The CKR5Δ32 deletion may act as a recessive restriction gene against HIV-1 infection and may exert a dominant phenotype of delaying progression to AIDS among infected individuals.
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*Background:* Host genetic factors, such as human leukocyte antigen (HLA) alleles, play an important role in mediating the course of human immunodeficiency virus-1 (HIV-1) disease progression through largely undefined mechanisms. *Objectives:* The objective of the following study is to examine the association of HLA markers with HIV-1 ribonucleic acid (RNA) plasma viral load and other factors associated with course of disease progression in HIV-1 infection. *Design and Methods:* A group of 139 HIV-1 seroconverters from the multicenter acquired immunodeficiency syndrome (AIDS) cohort study had been typed for a variety of HLA markers. HIV-1 RNA plasma viral load was measured from frozen plasma specimens obtained approximately 9 months following seroconversion. CD4^+^ cell counts were available from the same study visit. Statistical analysis was performed using survival techniques and linear regression models to quantify the relative associations of an HLA score profile, HIV-1 RNA plasma viral load, CD4^+^ cell count and age with each other and with rate of progression to AIDS and death. *Results:* Cox proportional hazards models showed statistically significant differences in time to AIDS by HLA score profile category per unit increase (relative hazard \[RH\] 0.64; *P* \< 0.0001), HIV-1 RNA plasma viral load per 10-fold increase (RH, 2.04; *P* = 0.0003), and CD4^+^ cell count/100 cell (×10^6^/l) increase (RH, 0.90; *P* = 0.02). Multivariate linear regression showed that viral load was 39% lower (*P* = 0.0001) for each unit increase in HLA score profile and 13% lower (*P* = 0.002) for each 100 cell (×10^6^/l) increase in CD4^+^ cell count. *Conclusions:* The means by which the HLA score profile influences the time to AIDS is probably through immunologic responses that affect the rate of HIV-1 replication, as manifested by the HIV-1 RNA plasma viral load during the first 6-12 months following acute infection.
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*Objective:* The objective of this study is to examine temporal variation in the effects of *CCR5-Δ32* and *CCR2-64I* chemokine receptor gene polymorphisms on human immunodeficiency virus-1 (HIV-1) disease progression. *Design:* Pooled analysis of individual patient data from 10 cohorts of HIV-1 seroconverters from the United States, Europe, and Australia. *Methods:* We studied HIV-1 seroconverters of European (*n* = 1635) or African (*n* = 215) ancestry who had been genotyped for *CCR5-Δ32* and *CCR2-64I*. We used Cox proportional hazards models with time-varying coefficients to determine whether the genetic protection against acquired immunodeficiency syndrome (AIDS) (1987 case definition) and death varied with time since seroconversion. *Results:* Protection against AIDS conferred by *CCR5-Δ32* held constant at a 31% (relative hazard \[RH\], 0.69, 95% confidence interval \[CI\], 0.54, 0.88) reduction in risk over the course of HIV-1 infection, whereas protection against death held constant at a 39% reduction in risk (RH, 0.61, 95% CI 0.45, 0.88). When the period from AIDS to death was isolated, the survival benefit of *CCR5-Δ32* diminished 2 years after AIDS. Protection against AIDS conferred by *CCR2-64I* was greatest early in the disease course. Compared with individuals without *CCR5-Δ32* or *CCR2-64I*, individuals with one or two copies of *CCR2-64I* had a 58% lower risk of AIDS during the first 4 years after seroconversion (RH, 0.42, 95% CI: 0.23, 0.76), a 19% lower risk during the subsequent 4 years (RH, 0.81, 95% CI: 0.59, 1.12), and no significant protection thereafter. *Conclusion:* The protection against AIDS provided by *CCR5-Δ32* is continuous during the course of infection. In contrast, the protection provided by *CCR2-64I* is greatest early in the course of infection.
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*Background:* The rate of immunological deterioration and progression to acquired immunodeficiency syndrome differs markedly between human immunodeficiency virus (HIV)-positive individuals, and may be influenced by cofactors, HIV phenotype and host T-cell response. Tumor necrosis factor (TNF-α) and lymphotoxin stimulate HIV replication and may induce apoptosis of HIV-infected and uninfected lymphocytes *in vitro*, thus accelerating disease progression and CD4 depletion. Variability in TNF production between individuals is to a degree genetically determined and may be predicted from polymorphisms of microsatellite regions surrounding the human TNF gene locus. *Methods:* We examined TNF microsatellite polymorphisms in 24 HIV-positive patients with slower disease progression (CD4 count \> 400 × 10^6^/l at ≥ 6 years), 20 HIV-positive patients with faster progression (CD4 count \<−200 ×10^6^/l within 5 years) and 109 healthy controls resident in north-west England. Typing was performed by polymerase chain reaction amplification of TNF a, b, c, and d microsatellites and alleles were defined using fluorescence-based semi-automated microsatellite mapping techniques. *Results:* No significant differences in TNF a, b, and d allele frequencies were observed between faster and slower progressors, or with healthy controls. The frequency of the TNF c2 allele was significantly different between HIV-positive slower (60.9%) and faster (15%) progressors (*P* = 0.002) with an odds ratio of 0.1 (95% confidence interval \[CI\]: 0-0.6). TNF c2 was also less frequent in faster progressors than in healthy controls (45.9%, *P* = 0.006) with an odds ratio of 0.2 (95% CI: 0-0.8). *Conclusions:* This is the first report demonstrating a strong association between the TNF c2 allele and the rate of HIV progression. Although, it is possible that this finding may have arisen as a result of linkage disequilibrium with other alleles within the major histocompatibility complex that exert a more powerful effect upon progression, evidence is mounting to suggest that both TNF-α and lymphotoxin are closely involved in HIV disease progression and CD4 depletion. Our results serve to highlight the potential importance of genetic polymorphism, particularly of the TNF locus, in influencing the progression of HIV infection.
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*Objectives:* To evaluate the effect on human immunodeficiency virus (HIV) progression of single nucleotide polymorphisms in promoters of the genes for tumor necrosis factor (TNF)-alpha and interleukin (IL)-10 and known to influence cytokine production. *Methods:* Survival was documented for 4.3 years after baseline for 198 HIV-1-infected and 180 HIV-uninfected individuals from the Mupfure schistosomiasis and HIV cohort in rural Zimbabwe. Polymorphisms determined were − 592C \> A and − 1082A \> G for IL-10 and − 238G \> A and - 308G \> A for TNF-alpha. CD4 cell counts, plasma HIV ribonucleic acid (RNA), soluble TNF receptor II (sTNF-rII), IL-8 and IL-10 were also measured. *Results:* Mortality was lower in carriers of the IL-10 - 1082G high-producer allele (hazard ratio, 0.47; *P* \< 0.01). CD4 cell count decrease in participants reporting for the follow-up at 3 years was attenuated in carriers of this allele (*P* \< 0.01). In univariate analysis, plasma IL-10, IL-8, and sTNF-rII correlated negatively with CD4 cell count, positively with HIV RNA, and higher levels predicted mortality. In multivariate analysis only sTNF-rII was an independent predictor of HIV progression markers and mortality. Indeed, sTNF-rII predicted mortality (*P* \< 0.01) at a level of significance comparable to HIV RNA (*P* \< 0.01) and CD4 cell count (*P* \< 0.05). *Conclusions:* In carriers of IL-10 - 1082G, an allele linked to increase IL-10 production, survival was doubled and CD4 cell decrease was attenuated compared with noncarriers. Only sTNF-rII and not plasma IL-10 was an independent predictor of HIV progression markers and mortality. This study supports immune activation as a driving force in HIV pathogenesis and indicates a protective role of IL-10-1082G that should be evaluated in other cohorts.
